Adma Biologics (ADMA) Capital Expenditures (2011 - 2026)

Adma Biologics (ADMA) has 13 years of Capital Expenditures data on file, last reported at $1.1 million in Q4 2025.

• Quarterly Capital Expenditures fell 60.68% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.6 million (up 174.43% YoY) and the FY2025 annual result came in at $22.6 million, up 174.43% from the prior year.
• Capital Expenditures retreated to $1.1 million in Q4 2025, from $14.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $14.4 million in Q3 2025 to a low of $757000.0 in Q3 2023.
• A 5-year average of $3.1 million and a median of $2.7 million in 2021 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures plunged 77.87% — and 2025, when it surged 1260.61%.
• Tracing ADMA's Capital Expenditures over 5 years: stood at $3.7 million in 2021, then gained by 1.98% to $3.7 million in 2022, then tumbled by 68.07% to $1.2 million in 2023, then soared by 130.33% to $2.8 million in 2024, then sank by 60.68% to $1.1 million in 2025.
• The last three Capital Expenditures figures came in at $1.1 million (Q4 2025), $14.4 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.